Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have received a consensus recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $41.5556.

Several analysts recently issued reports on TEVA shares. Truist Financial raised their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday. Piper Sandler reissued an “overweight” rating and issued a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. UBS Group raised their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. Wall Street Zen downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “hold” rating in a report on Saturday. Finally, Scotiabank raised their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings beat and revenue upside driven by branded products (Austedo, Ajovy, Uzedy), which lifted investor sentiment and underpins near‑term earnings growth. Read More.
• Positive Sentiment: Multiple broker upgrades and higher price targets — UBS, Truist, JPMorgan and Piper Sandler raised targets/ratings over the last day, signaling analyst confidence in a re‑rating and further upside for the stock. Read More. Read More.
• Positive Sentiment: Teva agreed to acquire Emalex for ~\$900M to add ecopipam (paediatric Tourette’s) — a late‑stage, de‑risked asset that bolsters the specialty/innovative portfolio and supports the narrative that Teva is shifting toward higher‑margin branded growth. Read More.
• Neutral Sentiment: Teva published its 2025 Healthy Future Report and says it met all sustainability‑linked bond targets — positive for ESG profile and potentially credit metrics, but unlikely to move near‑term revenues. Read More.
• Neutral Sentiment: Blackstone put significant financing behind Teva in a recent deal — signals institutional interest/validation but primarily affects capital structure and optionality rather than immediate EPS. Read More.
• Neutral Sentiment: Industry reports list Teva among leaders in oral solid dosage contract manufacturing — positive for long‑term service demand exposure but not an immediate earnings catalyst. Read More.
• Negative Sentiment: Generics revenue remains weak even as branded sales grow — raises questions about sustainability of overall top‑line growth if branded momentum slows. Read More.
• Negative Sentiment: After a rapid share run‑up, some analysts and coverage pieces note valuation/volatility risk — investors should weigh near‑term upside from upgrades against stretched multiples and execution risk. Read More.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $35.00 on Friday. The firm has a market cap of $40.24 billion, a price-to-earnings ratio of 26.31, a PEG ratio of 3.08 and a beta of 0.86. The stock has a 50 day moving average of $31.15 and a 200-day moving average of $29.39. The company has a current ratio of 1.01, a quick ratio of 0.80 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a 52 week low of $14.99 and a 52 week high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The business had revenue of $3.98 billion for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, analysts forecast that Teva Pharmaceutical Industries will post 2.6 EPS for the current year.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 62,102 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the sale, the insider owned 224,940 shares of the company’s stock, valued at $6,779,691.60. The trade was a 21.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the sale, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. The trade was a 16.78% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is currently owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds have recently added to or reduced their stakes in TEVA. AQR Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 24.6% during the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after acquiring an additional 4,732 shares in the last quarter. Focus Partners Wealth raised its stake in Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after acquiring an additional 1,739 shares in the last quarter. Franklin Resources Inc. bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $255,000. Flow Traders U.S. LLC bought a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at $238,000. Finally, Cerity Partners LLC raised its stake in Teva Pharmaceutical Industries by 2.9% during the 2nd quarter. Cerity Partners LLC now owns 45,837 shares of the company’s stock valued at $768,000 after acquiring an additional 1,291 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.